Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy
NCT00157508Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nitroaspirin in type 2 diabetes mellitus (T2DM) and diabetic nephropathy (DN) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Urinary Albumin Excretion at 4 weeks, Glucose disposal rate at 4 weeks and 1 more. Started Mar 2003; status: terminated.
02
Drugs
nitroaspirin
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00157508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00157508.